(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 13.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.96%.
Karyopharm Therapeutics's revenue in 2026 is $146,621,000.On average, 7 Wall Street analysts forecast KPTI's revenue for 2026 to be $3,086,493,077, with the lowest KPTI revenue forecast at $2,751,714,727, and the highest KPTI revenue forecast at $3,279,965,931. On average, 6 Wall Street analysts forecast KPTI's revenue for 2027 to be $3,942,037,748, with the lowest KPTI revenue forecast at $3,362,980,074, and the highest KPTI revenue forecast at $4,725,682,191.
In 2028, KPTI is forecast to generate $4,857,461,474 in revenue, with the lowest revenue forecast at $3,972,204,090 and the highest revenue forecast at $5,801,463,839.